Neuren Pharmaceuticals Limited
Clinical trials sponsored by Neuren Pharmaceuticals Limited, explained in plain language.
-
Hope for rare genetic disorder: new drug trial targets core symptoms
Disease control Recruiting nowThis study tests an oral drug called NNZ-2591 in 160 children aged 3 to 12 with Phelan-McDermid syndrome, a rare genetic condition. The drug is compared to a placebo to see if it improves communication and daily function. The trial is double-blind, meaning neither the families no…
Phase: PHASE3 • Sponsor: Neuren Pharmaceuticals Limited • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
New drug shows promise for rare genetic disorder in kids
Disease control Recruiting nowThis phase 3 study is testing an oral drug called NNZ-2591 in 180 children aged 3 to 12 with Phelan-McDermid syndrome, a rare genetic condition that causes developmental delays and other challenges. The main goal is to see if the drug is safe and tolerable over the long term. Res…
Phase: PHASE3 • Sponsor: Neuren Pharmaceuticals Limited • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC